CVS Health

Overview

CVS Health is the most vertically integrated pharma-facing services entity in the U.S. market, operating simultaneously as a pharmacy benefit manager (CVS Caremark), a national specialty pharmacy network (CVS Specialty), an infusion pharmacy (Coram), a rare disease management program (Accordant Health Services), a commercial health insurer (Aetna), a primary care provider (Oak Street Health), and a home-based health assessment platform (Signify Health). CVS reported $372.8 billion in total revenue for full-year 2024 and approximately $473 billion gross across segments in 2025, making it the largest health services company by revenue in the United States.

For pharma manufacturers, CVS is simultaneously a critical commercial partner and a formidable adversary. Its PBM controls formulary access for approximately 87 million plan members; its specialty pharmacy processes the largest volume of specialty fills of any single entity in the country; and its accumulator/maximizer programs systematically reduce the effectiveness of manufacturer-funded patient assistance.

Services & Capabilities

CVS Caremark PBM

CVS Caremark is the largest legacy PBM by covered lives, serving approximately 87-90 million plan members. The PBM sits within the Health Services segment alongside Cordavis (biosimilar commercialization), Oak Street Health, Signify Health, and MinuteClinic.

Formulary Management: Maintains Standard Control Formulary alongside client-specific formularies. 2025 managed formularies projected to deliver $4.3B in client savings. Preference shifting toward lower-list-price drugs over high-rebate/high-WAC alternatives under the TrueCost pricing model — Caremark’s acquisition-cost-based, drug-level net cost pricing platform. As of late 2025, 90%+ of commercial clients use two or more TrueCost features.

FTC Settlement (March 2026): CVS Caremark reached proposed consent agreement regarding insulin pricing. Terms require delinking Caremark compensation from manufacturer rebate negotiations and restricting preferential treatment for high-priced drugs. No financial penalty anticipated.

CVS Specialty

The largest specialty pharmacy network in the U.S. by volume. Key metrics:

• 55+ custom product launches in past 24 months (oncology, rare disease, gene therapy LDD)
• 50% of specialty prescriptions processed without additional prescriber outreach via EHR connectivity
• 97% medication possession ratio for patients in digital clinical messaging programs
• 23 walk-in specialty pharmacy sites near major oncology/academic medical centers
• Access to 250+ oncology medications
• Nearly 24,000 oncology prescribers nationally

Mail and specialty channel revenue: $70.9B (FY2024), growing to $79.3B (FY2025, +11.9% YoY).

Cell and Gene Therapy: Dedicated Cell and Gene Therapy Experience Center in Fairfield, NJ. Claims more oncology, rare disease, and gene therapy LDD launches over the past five years than any other specialty pharmacy.

Coram CVS Specialty Infusion Services: Home infusion and enteral nutrition services for subcutaneous and IV-administered specialty biologics.

Hub and Patient Support

CVS Specialty operates hub-equivalent programs through its CareTeam model: benefits investigation, PA support, copay assistance enrollment, adherence management. Includes 24/7 patient/prescriber access, digital engagement tools (97% MPR outcomes), CVS Specialty Central prescriber dashboard, and Specialty Connect patient routing between CVS Specialty and retail locations.

Accordant Health Services (Rare Disease)

Specialized care management for 20 rare and complex conditions with 25+ years of history. Outcomes: 26% reduction in all-cause inpatient admissions/ER visits, average gross savings of $1,200 per eligible member per program year, net ROI of 2.7-3.7x.

Accumulator and Maximizer Programs

CVS Caremark is a significant operator of copay accumulator and maximizer programs. As of 2025, 84% of commercially insured beneficiaries are in plans with accumulators available, 81% with maximizers. Actual enrollment ~39% of covered lives for each. Most programs require routing through CVS Specialty, creating both a financial mechanism and channel-steerage tool.

Competitive Position

PBM Market Share

CVS Caremark dropped from #1 PBM (34% claims share, 2023) to #2 (27%, 2024) due to the Centene contract loss to Express Scripts. Claims volume: 2.34B (2023) to 1.90B (2025). The Big Three PBMs collectively control ~80% of U.S. equivalent prescription claims.

PBM	2023 Share	2024 Share	2025 Direction
CVS Caremark	~34%	~27%	Declining
Express Scripts	~23%	~30%	Growing
OptumRx	~23%	~23%	Stable

Specialty Pharmacy

CVS Specialty, Express Scripts/Accredo, and OptumRx collectively capture ~two-thirds of U.S. specialty pharmacy revenues. CVS Specialty’s principal advantage is depth of integration — patients stay within the CVS data and clinical ecosystem. Walgreens Specialty differentiates on PBM independence.

Recent Developments

• CEO Transition (October 2024): David Joyner (former PBM leader) replaced Karen Lynch. PBM-first orientation signals focus on pharmacy services as primary value driver.
• Centene Contract Loss (January 2024): 20M PBM lives shifted to Express Scripts. Largest single PBM contract loss in industry history.
• Aetna MA Collapse (2024): Segment adjusted OI fell from $5.6B (2023) to $307M (2024). Recovering in 2025 ($2.9B). Over $60B in debt from Aetna/Signify/Oak Street acquisitions.
• FTC Insulin Settlement (March 2026): Proposed consent agreement; no financial penalty.
• Consolidated Appropriations Act, 2026: Mandates 100% rebate pass-through in Part D, bans spread pricing, any-willing-pharmacy provisions by 2028-2029.
• Oak Street Closures (October 2025): 16 locations being closed; value-based care thesis under pressure.
• TrueCost Adoption: 90%+ of commercial clients using two or more TrueCost features by late 2025.

Financial Profile

Segment	FY2023 Revenue	FY2024 Revenue	FY2025 Revenue
Health Care Benefits	$105.6B	$130.7B	$143.4B
Health Services	$186.8B	$173.6B	$190.4B
Pharmacy & Consumer Wellness	$116.8B	$124.5B	$139.4B
Total (reported)	$357.8B	$372.8B	~$473B gross

Health Services adjusted OI: $7.3B (2023), $7.2B (2024), $7.2B (2025) — remarkably stable despite Centene loss, indicating specialty pharmacy growth offset PBM volume decline.

2025 guidance: Adjusted EPS $7.00-$7.20, cash flow from operations at least $9.0B, mid-teens Adjusted EPS CAGR target over three years.

Sources

Primary source: raw/research/02_cvs_health.md. Financial data from CVS Health investor relations, SEC filings, and earnings releases. Market data from Drug Channels Institute, IQVIA, IntuitionLabs, and AMA.